Clinical trials

The Statista dossier
  • Detailed references
  • Editorially prepared
  • Download as PDF / PPT

Statista dossier about clinical research

This dossier presents key facts and figures about clinical trials worldwide, with a focus on the United States. Clinical trials are also known as Phase I to IV within the research, development, and approval process for new drugs, medical devices, or procedures. This document gives you an overview about health R&D in general, number of clinical studies, success rates, costs, and many more.

Table of contents

  • 1. R&D overview
    • Total global pharmaceutical R&D spending 2008-2022

    • Industry sectors - expenditure on research and development 2013-2015

    • Top pharmaceutical R&D projects based on net present value May 2017

    • Research and development expenditure: U.S. pharmaceutical industry 1995-2015

    • Research and development in European pharmaceutical industry by country 2015

    • Total clinical research funding by National Institutes for Health 2013-2018

  • 2. Top R&D companies
    • Global top pharmaceutical companies based on R&D spending 2022

    • Top 50 global pharmaceutical and biotech companies by R&D intensity in 2016/2017

    • Top pharmaceutical companies in R&D spending growth 2016-2017

    • Roche: participation of patients in clinical trials 2009-2017

    • Leading global clinical research organizations based on revenue 2016

    • Investments made by clinical research organizations by phase 2009-2014

  • 3. Clinical studies
    • Comparison between the complexity of clinical trials 2001-2015

    • Increase in clinical trials' complexity 2001-2015

    • Number of registered clinical studies by location worldwide 2017

    • Percent of registered clinical studies worldwide by location 2017

    • Share of recruiting clinical studies worldwide by location 2017

    • Total number of registered clinical studies worldwide since 2000

    • Total number of registered clinical studies with posted results worldwide 2009-2017

  • 4. Success rates
    • U.S. drug development Phase success rates 2006-2015

    • U.S. drug development Phase II success rates 2006-2015, by disease area

    • U.S. drug development Phase III success rates from 2006 to 2015, by disease area

    • U.S. development Phase success rates for oncology and non oncology drugs 2006-2015

    • U.S. drug development Phase success rates, by drug classification 2006-2015

    • U.S. development phase success rates for drugs with and without biomarkers 2006-2015

  • 5. Costs
    • Pharmaceuticals: cost of drug development in the U.S. since 1975

    • Leading orphan drugs based on R&D phase III cost 2015

    • Average per-study costs by trial phase

    • Total per-study costs by clinical trial phase and therapeutic area

    • Clinical trial costs by select component and phase

    • Average per-patient clinical trial costs in U.S. 2013, by selected condition

    • Average per-patient biopharmaceutical clinical trial costs in the U.S. 2013, by phase

  • 6. Approvals, launches, setbacks
    • Number of new drugs launched in the U.S. 2003-2015

    • Pharmaceutical industry - number of new substances 1992-2016

    • First world new molecular entities launched 2004-2015

    • FDA first premarket approvals for medtech products granted 2005-2016

    • NDA/BLA filing to FDA approval times for new drugs in select disease areas 2006-2015

    • Number of unsuccessful Alzheimer’s drugs in development in the U.S. 1998-2014

    • Unsuccessful developing melanoma drugs in the U.S. 1998-2014

    • Unsuccessful developing lung cancer drugs in the U.S. 1998-2014

  • Language: English
  • Released: August 2017
  • Source(s): Statista
More than 7,500
Recommended studies and dossiers
Show more
Recent studies and dossiers
You may also be interested in...
With Statista, you get straight to the point: analyzing data, rather than searching for it.

Dr. Antonella Mei-Pochtler about Statista Senior Vice President, Boston Consulting Group

Any more questions?

Get in touch with us quickly and easily. We are happy to help!